Translating Regenerative Medicine to the Clinic

Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR. Pedro Baptista, PharmD, PhD, Marie Curie Alumni, is a Senior ARAID Researcher at IIS Aragon, Zaragoza, Spain, where he directs the Laboratory of Organ Bioengineering and Regenerative Medicine. He serves as a Visiting Professor of Biomedical Engineering at Universidad Carlos III de Madrid. Dr. Baptista earned his Pharmacy Degree from the University of Lisbon and completed his PhD training at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. He is Secretary General of the European Society of Artificial Organs (ESAO) and Chair of the European Association for the Study of the Liver (EASL) Regenerative Hepatology Consortium. Dr. Baptista has published extensively in high-impact journals on organ bioengineering, organoids, and regenerative hepatology, holds four patents, and has successfully spun off several related technologies into companies. Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine. Seventeen of his lab’s technologies have been translated to patients, including the first tissue-engineered organ for permanent implantation in a human. His research led to the discovery of a multipotent source of stem cells from amniotic fluid and placenta, advances in 3D printing of tissues and organs, and body-on-a-chip technologies. His work was twice listed among Time Magazine’s top 10 medical breakthroughs of the year, and he is a recipient of the Smithsonian Ingenuity Award. He has published over 900 journal articles, is the editor of 25 books, and holds over 250 national and international patents. Dr. Atala is a member of the National Academy of Medicine, the National Academy of Inventors, and the American Institute for Medical and Biological Engineering.

• Introduction: Regenerative Medicine for Cardiovascular Disease-A Good Start PART I: STEM CELLS:  Chapter 1: Introduction and Overview of Stem CellsChapter 2: Mechanistic Insights from Pathologic Perspective Chapter 3: Large Animal Models to Study Stem Cell TherapySection I. Body’s Native Repair MechanismsChapter 4. Evolution of understanding of the mechanisms of repair     Chapter 5: Impact of Age on Stem Cell FunctionSection II: Autologous Bone MarrowChapter 6: Bone Marrow Mononuclear CellsChapter 7: Chronic Limb IschemiaChapter 8: Chronic/Refractory AnginaChapter 9: Acute Myocardial InfarctionA. European Experience:  Andreas ZeiherB. US Experience: Jay Traverse Chapter 10: Chronic Ischemic Heart FailureSection III:  Autologous Adipose Derived Regenerative CellsChapter 11: Adipose TissueSection IV: Allogeneic Alternatives to Autologous Bone MarrowChapter 12: Overview of MSCs     Chapter 13: Allogeneic vs Autologous Source: Comparative EffectsChapter 14: Use of MSCs for AMIChapter 15: Combined Cell StrategiesChapter 16: Heart FailureSection V: Cardiac Progenitor CellsChapter 17:  C-Kit+ cellsChapter 18:  CardiospheresSection VI: Other Allogeneic Sources of Stem CellsChapter 19:  Umbilical Cord, Placenta, EndometriumSection VII. Genetic Engineering/Cell TransformationChapter 20:  Genetic Engineering of Fibroblasts to CardiomyocytesChapter 21:  Transformation to inducible Pleuripotent Stem CellsChapter 22:  Transformation to MAPC'sSection VIII: METHODS OF DELIVERY:  Chapter 23.  Transcoronary and EndocardialChapter 24.  Retrograde and EpicardialPart II. TISSUE ENGINEERING:Chapter 25.  Epicardial PatchChapter 26.  Matrix ScaffoldsChapter 27.  Matrix plus cellsChapter 28.  BiomaterialChapter 29:  OrganogenesisPart III. GENE THERAPY: Chapter 30:  Pre-clinical Identification of target genesChapter 31:  SERCA-2a gene for recovery of inotropic functionChapter 32:  SDF-1 Gene for Heart Failure Non-Inotropic MechanismsChapter 33:  Gene Therapy for Angiogenesis: Chronic Limb Ischemia Chapter 34:  Stem Cells Target Gene Transfected Stem CellsPart IV: FUTURE DIRECTIONS:Chapter 35:  CCTRN: Past, Present, and Vision for the FutureChapter 36:  Signature of Responders-lessons from Bio-RepositoryChapter 37:  Adjunctive therapy with LVADs for RecoveryChapter 38:  Trials in Non-Ischemic Heart Failure  Chapter 39:  Enhancing Stem Cell Homing for Tissue RepairChapter 40:  Stroke: Pre-Clinical and Clinical Trial DataSUMMARY